Increasing Placebo Response Rates and the Threat to Clinical Trials: How Will We Identify Effective Treatments for Rheumatic Disorders?

The article discusses the increasing rates of placebo responses in clinical trials for psoriasis and psoriatic arthritis, particularly noting that these rates are higher in low-income countries compared to high-income countries. This trend complicates the ability to identify effective treatments, as...

Descripción completa

Detalles Bibliográficos
Publicado en:Arthritis & Rheumatology Vol. 78; no. 1; pp. 1 - 4
Autores principales: Parkes, Matthew J., Felson, David T., LaValley, Michael P.
Formato: commentary editorial tables/charts Journal Article
Publicado: Wiley-Blackwell Jan2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191211787&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 191211787
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23265191
        H06R
      jtl: Arthritis & Rheumatology
      issn: 23265191
      maglogo: N
    pubinfo:
      dt: Jan2026
      vid: 78
      iid: 1
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        191211787
        188171411
        191211787
        191211787
        10.1002/art.43303
        191211787
      ppf: 1
      ppct: 3
      formats:
      tig:
        atl: Increasing Placebo Response Rates and the Threat to Clinical Trials: How Will We Identify Effective Treatments for Rheumatic Disorders?
      aug:
        au:
          Parkes, Matthew J.
          Felson, David T.
          LaValley, Michael P.
        affil: Centre for Biostatistics, Division of Population Health, Health Services Research & Primary Care, School of Health Sciences, University of Manchester and NIHR Manchester Biomedical Research Centre and NIHR HealthTech Research Centre in Emergency and Acute Care, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
      sug:
        subj:
          Arthritis, Psoriatic Drug Therapy
          Psoriasis Drug Therapy
          Research Subject Recruitment
          Randomized Controlled Trials
          Socioeconomic Factors
          Placebos
          Drug Efficacy
          Low and Middle Income Countries
          Developed Countries
          Patient-Reported Outcomes
          Study Design
      ab: The article discusses the increasing rates of placebo responses in clinical trials for psoriasis and psoriatic arthritis, particularly noting that these rates are higher in low-income countries compared to high-income countries. This trend complicates the ability to identify effective treatments, as the active treatment response does not keep pace with placebo responses in psoriatic arthritis trials. The article also explores factors influencing placebo responses, such as patient expectations and the method of placebo administration, and suggests strategies to minimize these responses in trials. Additionally, it highlights emerging approaches like target trial emulation as alternatives to traditional randomized trials, aiming to address limitations in trial design and patient diversity.
      pubtype: Academic Journal
      doctype:
        commentary
        editorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N